Stocks and Investing
Stocks and Investing
Tue, January 31, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Brian Abrahams Maintained (XENE) at Buy with Increased Target to $51 on, Jan 31st, 2023
Brian Abrahams of RBC Capital, Maintained "Xenon Pharmaceuticals Inc." (XENE) at Buy with Increased Target from $49 to $51 on, Jan 31st, 2023.
Brian has made no other calls on XENE in the last 4 months.
There are 5 other peers that have a rating on XENE. Out of the 5 peers that are also analyzing XENE, 0 agree with Brian's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Brian
- Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $60 on, Wednesday, December 14th, 2022
- Joseph Thome of "Cowen & Co." Initiated at Buy on, Monday, December 12th, 2022
- Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $50 on, Monday, November 28th, 2022
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $49 on, Friday, November 11th, 2022
- Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $52 on, Wednesday, October 19th, 2022
Contributing Sources